EUCTR2016-003175-22-DE进行中（未招募）1 期
Two-arm randomized phase II trial to assess the feasibility and efficacy of a treatment with Durvalumab a PDL1-Inhibitor plus Tremelimumab a CTLA-4- Inhibitor in combination with radiotherapy and a treatment with Durvalumab in combination with radiotherapy as first-line therapy for patients with non-resectable locally advanced HPV negative HNSCC- A COMPARISON WITH A HISTORICAL CONTROL GROUP--DuTRe-raD - DURTRE-RAD
Charite Universitätsmedizin Berlin0 个研究点目标入组 66 人开始时间: 2017年11月13日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 66
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients with locally advanced histopathologically confirmed HNSCC not candidate for primary surgical treatment
- •? No distant metastasis (M0)
- •? Patients that are planned for radiotherapy
- •? Tumor tissue available for central testing Patients with HPV/p16 negative disease (=70% positively stained cells) as determined by central testing
- •? Adequate normal organ and marrow function
- •? Measurable tumor according to RECIST
- •? Patients must be expected to complete the treatment.
- •? Age > 18 years at time of study entry
- •? Female patients must either be of non-reproductive potential or must have a negative serum pregnancy test upon study entry and be willing to use adequate contraceptive measurements as described in the protocol
- •? Non-sterilized males who are sexually active with a female partner of childbearing potential must be willing to use adequate contraceptive measurements as described in the protocol
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 38
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 22
排除标准
- •? •Participation in another clinical study with an investigational product during the last 3 months
- •Prior or current anticancer treatment to the head and neck area (e.g. radical attempted or tumor reductive surgery, neo-adjuvant chemotherapy, EGFR inhibitors or radiotherapy).
- •Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab or an anti-CTLA4, including tremelimumab
- •Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:
- •oPatients with vitiligo or alopecia
- •oPatients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement
- •oAny chronic skin condition that does not require systemic therapy
- •oPatients without active disease in the last 5 years may be included but only after consultation with the study physician
- •oPatients with celiac disease controlled by diet alone
- •History of primary immunodeficiency
- •History of allogeneic organ transplant
- •History of another primary malignancy except for
- •oMalignancy treated with curative intent and with no known active disease =5 years before the first dose of IP and of low potential risk for recurrence
- •oAdequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
- •oAdequately treated carcinoma in situ without evidence of disease
- •History of hypersensitivity to durvalumab or any excipient
- •Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent
- •Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
- •Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results
- •Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control as described in the protocol from screening to 90 days after the last dose of durvalumab monotherapy
- •Distant metastasis
- •Patients who are institutionalised by official order
- •Mean QT interval corrected for heart rate (QTc) =470 ms calculated from 3 electrocardiograms (ECGs) using Fredericia’s Correction
- •Receipt of live attenuated vaccination within
研究者
相似试验
进行中（未招募）
不适用
A phase 2 randomised trial to investigate the effects of recombinant human erythropoietin on infarct size in patients undergoing primary percutaneous coronary angiography for ST-segment elevation myocardial infarction. - Erythropoietin in acute MIAcute ST elevation myocardial infarctionMedDRA version: 9.1Level: LLTClassification code 10000891Term: Acute myocardial infarctionEUCTR2004-005259-32-GBImperial College Heathcare NHS Trust
进行中（未招募）
1 期
Etude de phase II randomisée d’évaluation de la faisabilité d’une chimiothérapie par docetaxel prednisone sur un mode hebdomadaire ou toutes les 3 semaines dans une population de patients âgés (+75ans) «vulnérables » ou « fragiles », définis selon les critères de la SIOG, porteurs d’un adénocarcinome de prostate métastatique réfractaire à la castration et progressif.adénocarcinome de prostate métastatique réfractaire à la castration et progressifMedDRA version: 12.1Level: LLTClassification code 10036909Term: Prostate cancer metastaticEUCTR2009-017092-24-FRFNCLCC (Fédération Nationale des Centres de Lutte Contre le Cancer)
进行中（未招募）
2 期
High powered ultrasound to treat pancreas cancerocally advanced pancreatic cancerMalignant neoplasm of pancreasCancerISRCTN56087634niversity of Oxford20
尚未招募
Unknown
INFINITE: A Phase II Randomised Crossover Trial to Assess Feasibility of Domiciliary Nasal High Flow for Chronic Breathlessness in People with Interstitial Lung Diseaseinterstitial lung diseaseACTRN12623000835640Alfred Health20
进行中（未招募）
1 期
CIinical trial to compare the efficacy and safety of chemotherapy plus quizartinib versus chemotherapy plus placebo in patients with acute myeloid leukemia without FLT3 mutatioMedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864Acute myeloid leukemiaEUCTR2018-002851-14-PTFUNDACIÓN PETHEMA272